CALC
CalciMedica, Inc.
Price Chart
Latest Quote
$0.76
-0.08 (-10.07%)
Current Price
| Previous Close | $0.84 |
| Open | $0.86 |
| Day High | $0.86 |
| Day Low | $0.75 |
| Volume | 105,499 |
Stock Information
| Shares Outstanding | 15.80M |
| Total Debt | $6.70M |
| Cash Equivalents | $8.16M |
| Net Income | $-19.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $11.93M |
| EPS (TTM) | $-1.31 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $11.78M |
| Income | $-19.54M |
| Book/sh | $-0.07 |
| Cash/sh | $0.52 |
| Employees | 16 |
Financial Ratios
| Quick Ratio | 1.54 |
| Current Ratio | 1.61 |
Returns & Margins
| ROA | -81.85% |
| ROE | -399.51% |
Ownership
| Insider Ownership | 14.27% |
| Institutional Ownership | 35.76% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.46 |
| P/B | -10.49 |
Analyst Data
| Recommendation | none |
| Target Price | $10.33 |
Technical Indicators
| SMA20 | $0.84 |
| SMA50 | $0.70 |
| SMA200 | $2.38 |
| RSI | 45.44 |
| ATR | 0.1112 |
| Shares Float | 8.94M |
| Short Float | 2.96% |
| Short Ratio | 1.01 |
| Rel Volume | 0.34 |
Performance History
| Week | -15.36% |
| Month | +22.37% |
| Quarter | +2.30% |
| 6 Months | -85.54% |
| YTD | -88.80% |
| Year | -55.33% |
| 10 Years | -87.07% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.75 | 111,200 |
| 2026-06-17 | $0.84 | 51,800 |
| 2026-06-16 | $0.86 | 143,600 |
| 2026-06-15 | $0.87 | 52,400 |
| 2026-06-12 | $0.87 | 91,900 |
| 2026-06-11 | $0.89 | 241,900 |
| 2026-06-10 | $0.93 | 215,500 |
| 2026-06-09 | $0.91 | 242,400 |
| 2026-06-08 | $0.96 | 564,900 |
| 2026-06-05 | $1.06 | 2,994,500 |
| 2026-06-04 | $0.85 | 160,500 |
| 2026-06-03 | $0.85 | 113,800 |
| 2026-06-02 | $0.80 | 243,300 |
| 2026-06-01 | $0.84 | 154,800 |
| 2026-05-29 | $0.82 | 311,100 |
| 2026-05-28 | $0.87 | 232,600 |
| 2026-05-27 | $0.75 | 129,200 |
| 2026-05-26 | $0.76 | 291,500 |
| 2026-05-22 | $0.63 | 50,100 |
| 2026-05-21 | $0.63 | 115,800 |
| 2026-05-20 | $0.64 | 70,100 |
| 2026-05-19 | $0.62 | 72,300 |
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,422,000 | $0 | $110,000 | $132,000 |
| Total Expenses | $23,121,000 | $24,204,000 | $38,075,000 | $14,193,000 |
| Other Income Expense | $-5,732,000 | $9,490,000 | $3,718,000 | $6,501,000 |
| Other Non Operating Income Expenses | $268,000 | $1,014,000 | $550,000 | $-28,000 |
| Net Non Operating Interest Income Expense | $-709,000 | $1,014,000 | $-110,000 | $-132,000 |
| Interest Expense Non Operating | $1,422,000 | $0 | $110,000 | $132,000 |
| Operating Expense | $23,121,000 | $24,204,000 | $38,075,000 | $14,193,000 |
| General And Administrative Expense | $7,887,000 | $9,726,000 | $22,216,000 | $5,843,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-7,824,000 |
| Net Interest Income | $-709,000 | $1,014,000 | $-110,000 | $-132,000 |
| Interest Income | $713,000 | $1,014,000 | - | $575,000 |
| Normalized Income | $-23,562,000 | $-23,190,000 | $-37,525,000 | $-14,353,000 |
| Net Income From Continuing And Discontinued Operation | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-7,824,000 |
| Total Operating Income As Reported | $-23,121,000 | $-24,204,000 | $-38,075,000 | $-14,193,000 |
| Net Income Common Stockholders | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-9,142,000 |
| Net Income | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-7,824,000 |
| Net Income Including Noncontrolling Interests | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-7,824,000 |
| Net Income Continuous Operations | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-7,824,000 |
| Pretax Income | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-7,824,000 |
| Interest Income Non Operating | $713,000 | $1,014,000 | - | $575,000 |
| Operating Income | $-23,121,000 | $-24,204,000 | $-38,075,000 | $-14,193,000 |
| Special Income Charges | - | - | - | $-2,963,000 |
| Per Share | ||||
| Diluted EPS | $-1.97 | $-1.22 | $-7.66 | $-111.16 |
| Basic EPS | $-1.97 | $-1.22 | $-7.66 | $-111.16 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-22,094,000 | $-23,132,000 | $-41,185,000 | $-14,169,000 |
| Total Unusual Items | $-6,000,000 | $9,490,000 | $3,168,000 | $6,529,000 |
| Total Unusual Items Excluding Goodwill | $-6,000,000 | $9,490,000 | $3,168,000 | $6,529,000 |
| Reconciled Depreciation | $46,000 | $58,000 | $58,000 | $52,000 |
| EBITDA (Bullshit earnings) | $-28,094,000 | $-13,642,000 | $-38,017,000 | $-7,640,000 |
| EBIT | $-28,140,000 | $-13,700,000 | $-38,075,000 | $-7,692,000 |
| Diluted Average Shares | $15,011,321 | $11,245,915 | $4,486,258 | $82,245 |
| Basic Average Shares | $15,011,321 | $11,245,915 | $4,486,258 | $82,245 |
| Diluted NI Availto Com Stockholders | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-9,142,000 |
| Gain On Sale Of Security | $-6,000,000 | $9,490,000 | $3,168,000 | $6,529,000 |
| Research And Development | $15,234,000 | $14,478,000 | $15,859,000 | $8,350,000 |
| Selling General And Administration | $7,887,000 | $9,726,000 | $22,216,000 | $5,843,000 |
| Other Gand A | $3,509,000 | $5,862,000 | $5,344,000 | $3,558,000 |
| Salaries And Wages | $4,378,000 | $3,864,000 | $16,872,000 | $2,285,000 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $1,318,000 |
| Impairment Of Capital Assets | - | - | - | $0 |
| Restructuring And Mergern Acquisition | - | - | - | $2,963,000 |
| Write Off | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,641,000 | $14,410,000 | $8,157,000 | $-9,233,000 |
| Total Assets | $13,591,000 | $19,794,000 | $12,185,000 | $3,349,000 |
| Total Non Current Assets | $61,000 | $129,000 | $580,000 | $1,619,000 |
| Other Non Current Assets | $11,000 | $10,000 | $413,000 | $1,424,000 |
| Current Assets | $13,530,000 | $19,665,000 | $11,605,000 | $1,730,000 |
| Other Current Assets | $259,000 | $248,000 | $296,000 | $254,000 |
| Assets Held For Sale Current | $54,000 | $0 | - | - |
| Prepaid Assets | $201,000 | $748,000 | $71,000 | $503,000 |
| Cash Cash Equivalents And Short Term Investments | $13,016,000 | $18,669,000 | $11,238,000 | $1,327,000 |
| Cash And Cash Equivalents | $11,520,000 | $7,935,000 | $5,530,000 | $1,327,000 |
| Restricted Cash | - | - | $0 | $149,000 |
| Receivables | - | - | - | $39,000 |
| Accrued Interest Receivable | - | - | - | $39,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $9,700,000 | - | - | $5,157,000 |
| Long Term Debt And Capital Lease Obligation | $8,450,000 | - | - | $5,157,000 |
| Long Term Debt | $8,450,000 | - | - | $5,157,000 |
| Current Debt And Capital Lease Obligation | $1,250,000 | - | - | $203,000 |
| Current Debt | $1,250,000 | - | - | - |
| Other Current Borrowings | $1,250,000 | - | - | - |
| Net Debt | - | - | - | $3,830,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $20,232,000 | $5,384,000 | $4,028,000 | $12,582,000 |
| Total Non Current Liabilities Net Minority Interest | $16,450,000 | $1,700,000 | $0 | $7,802,000 |
| Derivative Product Liabilities | $8,000,000 | $1,700,000 | $0 | $2,645,000 |
| Current Liabilities | $3,782,000 | $3,684,000 | $4,028,000 | $4,780,000 |
| Payables And Accrued Expenses | $2,532,000 | $3,684,000 | $3,939,000 | $4,581,000 |
| Payables | $1,161,000 | $1,998,000 | $1,419,000 | $2,868,000 |
| Accounts Payable | $1,161,000 | $1,998,000 | $1,419,000 | $2,866,000 |
| Total Tax Payable | - | - | $77,000 | $2,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Other Current Liabilities | - | - | - | $199,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-6,641,000 | $14,410,000 | $8,157,000 | $-71,304,000 |
| Total Equity Gross Minority Interest | $-6,641,000 | $14,410,000 | $8,157,000 | $-9,233,000 |
| Stockholders Equity | $-6,641,000 | $14,410,000 | $8,157,000 | $-9,233,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $4,000 | $2,000 | $-37,000 |
| Retained Earnings | $-189,326,000 | $-159,764,000 | $-146,064,000 | $-111,707,000 |
| Other Equity Adjustments | - | $4,000 | $2,000 | $-37,000 |
| Preferred Stock Equity | - | - | - | $62,071,000 |
| Other | ||||
| Ordinary Shares Number | $15,437,410 | $13,481,917 | $5,754,505 | $1,549,745 |
| Share Issued | $15,437,410 | $13,481,917 | $5,754,505 | $1,549,745 |
| Tangible Book Value | $-6,641,000 | $14,410,000 | $8,157,000 | $-71,304,000 |
| Invested Capital | $3,059,000 | $14,410,000 | $8,157,000 | $-66,147,000 |
| Working Capital | $9,748,000 | $15,981,000 | $7,577,000 | $-3,050,000 |
| Total Capitalization | $1,809,000 | $14,410,000 | $8,157,000 | $-4,076,000 |
| Additional Paid In Capital | $182,681,000 | $174,166,000 | $154,218,000 | $40,402,000 |
| Capital Stock | $4,000 | $4,000 | $1,000 | $62,072,000 |
| Common Stock | $4,000 | $4,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $62,071,000 |
| Current Accrued Expenses | $1,371,000 | $1,686,000 | $2,520,000 | $1,713,000 |
| Net PPE | $50,000 | $119,000 | $167,000 | $195,000 |
| Gross PPE | $50,000 | $119,000 | $167,000 | $195,000 |
| Other Properties | $50,000 | $119,000 | $167,000 | $195,000 |
| Other Short Term Investments | $1,496,000 | $10,734,000 | $5,708,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $0 | $89,000 | $0 |
| Capital Lease Obligations | - | - | - | $203,000 |
| Current Capital Lease Obligation | - | - | - | $203,000 |
| Accumulated Depreciation | - | - | - | $0 |
| Leases | - | - | - | $0 |
| Construction In Progress | - | - | - | $0 |
| Machinery Furniture Equipment | - | - | - | $0 |
| Properties | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-21,206,000 | $-21,154,000 | $-25,808,000 | $-11,761,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-21,178,000 | $-21,146,000 | $-25,730,000 | $-11,757,000 |
| Cash Flow From Continuing Operating Activities | $-21,178,000 | $-21,146,000 | $-25,730,000 | $-11,757,000 |
| Operating Gains Losses | $5,223,000 | $-8,714,000 | $-1,146,000 | $-3,784,000 |
| Investing Activities | ||||
| Capital Expenditure | $-28,000 | $-8,000 | $-78,000 | $-4,000 |
| Investing Cash Flow | $9,551,000 | $-4,423,000 | $8,884,000 | $-4,000 |
| Cash Flow From Continuing Investing Activities | $9,551,000 | $-4,423,000 | $8,884,000 | $-4,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,523,000 | $27,954,000 | $25,445,000 | $18,000 |
| Financing Cash Flow | $15,212,000 | $27,974,000 | $20,900,000 | $8,476,000 |
| Cash Flow From Continuing Financing Activities | $15,212,000 | $27,974,000 | $20,900,000 | $8,476,000 |
| Net Common Stock Issuance | $5,523,000 | $27,954,000 | $25,445,000 | $18,000 |
| Common Stock Issuance | $5,523,000 | $27,954,000 | $25,445,000 | $18,000 |
| Net Other Financing Charges | - | - | $-4,545,000 | $-139,000 |
| Other | ||||
| Issuance Of Debt | $9,664,000 | $0 | $0 | $8,458,000 |
| Interest Paid Supplemental Data | $1,087,000 | $0 | - | - |
| End Cash Position | $11,520,000 | $7,935,000 | $5,530,000 | $1,476,000 |
| Beginning Cash Position | $7,935,000 | $5,530,000 | $1,476,000 | $4,761,000 |
| Changes In Cash | $3,585,000 | $2,405,000 | $4,054,000 | $-3,285,000 |
| Proceeds From Stock Option Exercised | $25,000 | $20,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $9,664,000 | $0 | $0 | $8,458,000 |
| Net Long Term Debt Issuance | $9,664,000 | $0 | $0 | $8,458,000 |
| Long Term Debt Issuance | $9,664,000 | $0 | $0 | $8,458,000 |
| Net Investment Purchase And Sale | $9,579,000 | $-4,415,000 | $8,962,000 | $0 |
| Sale Of Investment | $25,495,000 | $24,587,000 | $15,080,000 | $0 |
| Purchase Of Investment | $-15,916,000 | $-29,002,000 | $-6,118,000 | $0 |
| Net PPE Purchase And Sale | $-28,000 | $-8,000 | $-78,000 | $-4,000 |
| Purchase Of PPE | $-28,000 | $-8,000 | $-78,000 | $-4,000 |
| Change In Working Capital | $-623,000 | $-495,000 | $-267,000 | $605,000 |
| Change In Payables And Accrued Expense | $-1,159,000 | $-267,000 | $-3,264,000 | $2,135,000 |
| Change In Accrued Expense | $-319,000 | $-868,000 | $-1,837,000 | $1,202,000 |
| Change In Payable | $-840,000 | $601,000 | $-1,427,000 | $933,000 |
| Change In Account Payable | $-840,000 | $601,000 | $-1,427,000 | $933,000 |
| Change In Prepaid Assets | $536,000 | $-228,000 | $2,997,000 | $-1,530,000 |
| Other Non Cash Items | $336,000 | - | $110,000 | $132,000 |
| Stock Based Compensation | $2,971,000 | $2,313,000 | $12,039,000 | $1,807,000 |
| Unrealized Gain Loss On Investment Securities | $776,000 | $0 | $-2,022,000 | $-2,745,000 |
| Amortization Of Securities | $-345,000 | $-608,000 | $-145,000 | $0 |
| Depreciation Amortization Depletion | $46,000 | $58,000 | $58,000 | $52,000 |
| Depreciation And Amortization | $46,000 | $58,000 | $58,000 | $52,000 |
| Depreciation | $46,000 | $58,000 | $58,000 | $338,000 |
| Gain Loss On Investment Securities | $5,223,000 | $-8,714,000 | $-1,146,000 | $-3,784,000 |
| Net Income From Continuing Operations | $-29,562,000 | $-13,700,000 | $-34,357,000 | $-7,824,000 |
| Net Intangibles Purchase And Sale | - | - | - | $-1,944,000 |
| Purchase Of Intangibles | - | - | - | $-1,944,000 |
| Sale Of PPE | - | - | - | $430,000 |
| Change In Other Current Liabilities | - | - | - | $-2,268,000 |
| Asset Impairment Charge | - | - | - | $1,599,000 |
Fetched: 2026-06-17